Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Uveal Melanoma 1Pancreatic Neoplasms 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Endometrioid 1Adenocarcinoma of Lung 1

Interventions

pembrolizumab 1273Specimen Handling 871Carboplatin 832Magnetic Resonance Spectroscopy 808Cyclophosphamide 803Cisplatin 729Nivolumab 659Paclitaxel 631Radiotherapy 574Gemcitabine 572Biopsy 529Bevacizumab 476Dexamethasone 440fludarabine 407Docetaxel 378venetoclax 370Oxaliplatin 365Capecitabine 358Fluorouracil 355atezolizumab 344durvalumab 334Rituximab 333Doxorubicin 317Radiosurgery 309Pemetrexed 306Drug Therapy 303Ipilimumab 294Standard of Care 293Etoposide 285Radiation 281

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × RO5126766 × 1 year × Clear all
NCT06495125 2026-04-06

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Emory University

Phase 2 Recruiting
50 enrolled
Thoracic

Adenocarcinoma of Lung, Lung Neoplasms

NCT03875820 2026-03-10

FRAME

Institute of Cancer Research, United Kingdom

Phase 1 Active not recruiting
87 enrolled
Gastrointestinal

Pancreatic Neoplasms, Carcinoma, Endometrioid

NCT05798507 2025-12-15

Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma

Emory University

Phase EARLY_PHASE1 Active not recruiting
14 enrolled
CNS

Glioblastoma

NCT04720417 2025-07-15

Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma

Thomas Jefferson University

Phase 2 Terminated
13 enrolled 13 charts
Dermatologic

Uveal Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡